Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

This company has been moved to the archive! The financial data has not been updated since May 5, 2022.

Analysis of Long-term (Investment) Activity Ratios 

Microsoft Excel

Long-term Activity Ratios (Summary)

Zoetis Inc., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net fixed asset turnover 3.21 3.03 3.23 3.51 3.70
Net fixed asset turnover (including operating lease, right-of-use asset) 2.99 2.79 2.94 3.51 3.70
Total asset turnover 0.56 0.49 0.54 0.54 0.62
Equity turnover 1.71 1.77 2.31 2.67 3.00

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Zoetis Inc. net fixed asset turnover ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Zoetis Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Zoetis Inc. total asset turnover ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Zoetis Inc. equity turnover ratio deteriorated from 2019 to 2020 and from 2020 to 2021.

Net Fixed Asset Turnover

Zoetis Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in millions)
Revenue 7,776 6,675 6,260 5,825 5,307
Property, plant and equipment, less accumulated depreciation 2,422 2,202 1,940 1,658 1,435
Long-term Activity Ratio
Net fixed asset turnover1 3.21 3.03 3.23 3.51 3.70
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 11.00 8.73 11.23
Amgen Inc. 4.69 4.96 4.51
Bristol-Myers Squibb Co. 7.67 7.22 4.18
Eli Lilly & Co. 3.15 2.83 2.83
Gilead Sciences Inc. 5.27 4.90 4.91
Johnson & Johnson 4.95 4.40 4.65
Merck & Co. Inc. 2.53 2.67 3.11
Pfizer Inc. 5.46 3.01 3.71
Regeneron Pharmaceuticals Inc. 4.62 2.64 2.72
Thermo Fisher Scientific Inc. 4.71 5.45 5.38
Vertex Pharmaceuticals Inc. 6.92 6.47 5.59
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.86 4.21 4.22
Net Fixed Asset Turnover, Industry
Health Care 10.38 9.62 9.72

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 2021 Calculation
Net fixed asset turnover = Revenue ÷ Property, plant and equipment, less accumulated depreciation
= 7,776 ÷ 2,422 = 3.21

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Zoetis Inc. net fixed asset turnover ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Zoetis Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in millions)
Revenue 7,776 6,675 6,260 5,825 5,307
 
Property, plant and equipment, less accumulated depreciation 2,422 2,202 1,940 1,658 1,435
Operating lease right of use assets 181 192 189
Property, plant and equipment, less accumulated depreciation (including operating lease, right-of-use asset) 2,603 2,394 2,129 1,658 1,435
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 2.99 2.79 2.94 3.51 3.70
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 9.57 7.46 10.06
Amgen Inc. 4.23 4.58 4.11
Bristol-Myers Squibb Co. 6.66 6.30 3.76
Eli Lilly & Co. 2.93 2.63 2.66
Gilead Sciences Inc. 4.77 4.34 4.28
Johnson & Johnson 4.72 4.18 4.41
Merck & Co. Inc. 2.33 2.43 2.90
Pfizer Inc. 4.59 2.74 3.39
Regeneron Pharmaceuticals Inc. 4.52 2.58 2.66
Thermo Fisher Scientific Inc. 3.98 4.82 4.69
Vertex Pharmaceuticals Inc. 5.32 4.83 5.00
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.37 3.84 3.89
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 8.22 7.54 7.63

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 2021 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property, plant and equipment, less accumulated depreciation (including operating lease, right-of-use asset)
= 7,776 ÷ 2,603 = 2.99

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Zoetis Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level.

Total Asset Turnover

Zoetis Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in millions)
Revenue 7,776 6,675 6,260 5,825 5,307
Total assets 13,900 13,609 11,545 10,777 8,586
Long-term Activity Ratio
Total asset turnover1 0.56 0.49 0.54 0.54 0.62
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.38 0.30 0.37
Amgen Inc. 0.40 0.39 0.37
Bristol-Myers Squibb Co. 0.42 0.36 0.20
Eli Lilly & Co. 0.58 0.53 0.57
Gilead Sciences Inc. 0.40 0.36 0.36
Johnson & Johnson 0.52 0.47 0.52
Merck & Co. Inc. 0.46 0.52 0.55
Pfizer Inc. 0.45 0.27 0.31
Regeneron Pharmaceuticals Inc. 0.63 0.50 0.53
Thermo Fisher Scientific Inc. 0.41 0.47 0.44
Vertex Pharmaceuticals Inc. 0.56 0.53 0.50
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.45 0.39 0.40
Total Asset Turnover, Industry
Health Care 0.76 0.70 0.71

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 2021 Calculation
Total asset turnover = Revenue ÷ Total assets
= 7,776 ÷ 13,900 = 0.56

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Zoetis Inc. total asset turnover ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level.

Equity Turnover

Zoetis Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in millions)
Revenue 7,776 6,675 6,260 5,825 5,307
Total Zoetis Inc. equity 4,543 3,769 2,708 2,185 1,770
Long-term Activity Ratio
Equity turnover1 1.71 1.77 2.31 2.67 3.00
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 3.65 3.50
Amgen Inc. 3.63 2.58 2.30
Bristol-Myers Squibb Co. 1.29 1.12 0.51
Eli Lilly & Co. 3.15 4.35 8.56
Gilead Sciences Inc. 1.28 1.34 0.98
Johnson & Johnson 1.27 1.31 1.38
Merck & Co. Inc. 1.28 1.90 1.81
Pfizer Inc. 1.05 0.66 0.82
Regeneron Pharmaceuticals Inc. 0.86 0.77 0.71
Thermo Fisher Scientific Inc. 0.96 0.93 0.86
Vertex Pharmaceuticals Inc. 0.75 0.71 0.68
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.35 1.31 1.26
Equity Turnover, Industry
Health Care 2.10 2.06 2.06

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 2021 Calculation
Equity turnover = Revenue ÷ Total Zoetis Inc. equity
= 7,776 ÷ 4,543 = 1.71

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Zoetis Inc. equity turnover ratio deteriorated from 2019 to 2020 and from 2020 to 2021.